Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SCN4A | P35499 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29291524 | 0.76 | MAPT (0.37) | MAPTGAALMNATSHRMAPK1 | |
| SCHEMBL4928116 | 0.76 | MAPT (0.37) | MAPTGAALMNATSHRMAPK1 | |
| SCHEMBL31448339 | 0.71 | MAPT (0.43) | MAPTGAAMAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL28059865 | 0.71 | MAPT (0.43) | MAPTGAAMAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL1726909 | 0.71 | GAA (0.46) | MAPTGAAALDH1A1 | |
| SCHEMBL4796337 | 0.70 | MAPT (0.42) | MAPTGAAMAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL29896250 | 0.70 | MAPT (0.42) | MAPTGAAMAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL29789697 | 0.70 | MAPT (0.50) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL2255782 | 0.70 | MAPT (0.50) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL984966 | 0.69 | MAPT (0.41) | MAPTGAALMNAMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968944-B1 | ALKYLSULPHONAMIDE QUINOLINES | ASTRAZENECA AB (SE) | 2016-04-20 | — | — | EP | disclosed |
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-08-07 | — | — | US | disclosed |
| US-20100041698-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-02-18 | — | — | US | disclosed |
| US-20070259882-A1 | 3-SUBSTITUTED QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. | 2007-11-08 | — | — | US | disclosed |
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. | 2007-07-12 | — | — | US | disclosed |
| US-20070060593-A1 | 4-Carboxamido quinoline derivatives for use as nk-2 and nk-3 | SMITHKLINE BEECHAM CORPORATION | 2007-03-15 | — | — | US | disclosed |
| EP-1377555-B1 | A DIOXINO[2,3-G]QUINOLINE-9-CARBOXYLIC ACID DERIVATIVE AS NK3 RECEPTOR ANTAGONIST | GLAXOSMITHKLINE SPA (IT) | 2007-01-24 | — | — | EP | disclosed |
| US-20060229315-A1 | 3-Substituted Quinoline-4-Carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists | GLAXOSMITHKLINE S.P.A. (IT) | 2006-10-12 | — | — | US | disclosed |
| US-20060135771-A1 | Quinoline derivatives as nk-2 and nk-3 receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2006-06-22 | — | — | US | disclosed |
| EP-1659120-A1 | 3-substituted quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | GlaxoSmithKline S.p.A. (IT) | 2006-05-24 | — | — | EP | disclosed |
| EP-1377567-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GlaxoSmithKline S.p.A. (IT) | 2004-01-07 | — | — | EP | disclosed |
| EP-1377555-A1 | NOVEL COMPOUNDS | GlaxoSmithKline S.p.A. (IT) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002083664-A1 | 3-SUBSTITUTED QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. (IT) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083663-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. (IT) | 2002-10-24 | — | — | WO | disclosed |
| US-20020156095-A1 | 2-aminoquinolinecarboxamides: neurokinin receptor ligands | NEUROGEN CORPORATION | 2002-10-24 | — | — | US | disclosed |
| US-20020156095-A1 | 2-aminoquinolinecarboxamides: neurokinin receptor ligands | NEUROGEN CORPORATION | 2002-10-24 | — | — | US | disclosed |
| WO-2002083645-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE S.P.A. (IT) | 2002-10-24 | — | — | WO | disclosed |
| US-6369053-B1 | CENTRAL NERVOUS SYSTEM AND PERIPHERAL DISEASES; ALSO USEFUL AS PROBES FOR THE LOCALIZATION OF CELL SURFACE RECEPTORS; NONPEPTIDE NK-3 RECEPTOR ANTAGONISTS | NEUROGEN CORPORATION | 2002-04-09 | — | — | US | disclosed |
| US-6369053-B1 | CENTRAL NERVOUS SYSTEM AND PERIPHERAL DISEASES; ALSO USEFUL AS PROBES FOR THE LOCALIZATION OF CELL SURFACE RECEPTORS; NONPEPTIDE NK-3 RECEPTOR ANTAGONISTS | NEUROGEN CORPORATION | 2002-04-09 | — | — | US | disclosed |
| WO-2000064877-A1 | 2-AMINOQUINOLINECARBOXAMIDES: NEUROKININ RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, HTR1A, HTR2C | MAPT 73/4885GAA 3123/4885LMNA 4251/4885 |
| US-20070060593-A1 | 4-Carboxamido quinoline derivatives for use as nk-2 and nk-3 | KCNK3, KCNQ3, KCNK2 | MAPT 4836/4885GAA 1696/4885LMNA 3735/4885 |
| US-20020156095-A1 | 2-aminoquinolinecarboxamides: neurokinin receptor ligands | KCNQ3, OPRK1, KCNQ1 | MAPT 898/4885GAA 1167/4885LMNA 2735/4885 |
| US-20060135771-A1 | Quinoline derivatives as nk-2 and nk-3 receptor antagonists | KCNK3, KCNQ3, KCNK2 | MAPT 4843/4885GAA 1752/4885LMNA 3430/4885 |
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | KCNQ3, KCNK3, KCNK2 | MAPT 4420/4885GAA 1364/4885LMNA 2768/4885 |
| US-20100041698-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, HTR1A, HTR2C | MAPT 73/4885GAA 3123/4885LMNA 4251/4885 |
| US-20070259882-A1 | 3-SUBSTITUTED QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | KCNK3, KCNJ2, KCNK2 | MAPT 4604/4885GAA 1514/4885LMNA 3412/4885 |
| US-20060229315-A1 | 3-Substituted Quinoline-4-Carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists | KCNK3, KCNJ2, KCNK2 | MAPT 4604/4885GAA 1514/4885LMNA 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.